GTC Biotherapeutics, Inc., of Framingham, MA, and Paris-based LFB-Biotechnologies will collaborate on the development of therapeutic products using recombinant plasma proteins and monoclonal antibodies (identical antibodies used in the production of pharmaceuticals). Their first collaborative product is a recombinant human factor VIIa (rhFVIIa) therapy. The rhFVIIa will be developed from the milk of GTC’s transgenic rabbits. Transgenic animals, such as cows and rabbits, are produced using externally introduced genes that are designed to trigger the production of specific human proteins in their milk. These proteins are then purified for other therapeutic uses, such as the treatment of patients with bleeding disorders.
The agreement states that GTC will develop a production system for the products and will hold exclusive commercial rights in North America. LFB will be responsible for clinical development and regulatory review of the first program of the collaboration and will have exclusive commercial rights in Europe. GTC Biotherapeutics, Inc., develops, produces and commercializes proteins through transgenic animal technology. LFB is a leading European producer of plasma-derived medical products, including those for hemostasis.
Source: America’s Blood Centers Newsletter, October 6, 2006